Dr. Xingli Wang

I mean, Fusang Pharma, like most of the Chinese pharmaceutical companies, has a relatively short history.

It started about 30 years ago.

We started with diagnostic business development and with the diagnostic kit on the hepatitis C, and then we moved on to the generic drugs business by acquiring several different existing pharmaceutical companies which are making the generic drugs

I think that has been this major pillar for Fusong Pharma in relation to the drug development for that about almost spanning for almost two decades.

During the same time, we also acquired or established the medical devices

and also hospitals and vaccines.

So that really made up the whole Fusang's five business units, including established medicine, innovative medicines, and of course, tech, healthcare, and vaccines.

But back to how we started on the innovative medicine side, back to about 10 or 15 years ago, when we really realized innovation is a way to go for the long-term growing, and we can't just copy.

and do the generics.

So that's how we started the first of the Henleys.

You know, we recruited a few US-based scientists and came back to China to start the Henleys as being, you know, through the last 15 years, it became very successful.

The biopharma in relation to the antibodies related.

And then also we established a small molecule business unit.

And not business unit, I mean, I would say branch or arm of the activities.

and that one has been on the rocky road for a little bit until last a few years and we mostly on followers i mean some of the faster some of the slower in relation to the uh you know the medicine aspect novel drugs and it was 80 has been on oncology as you going to talk about oncology

And here, you know, we've been focusing on oncology for quite a long time.

And from small molecule perspective, we started to produce NDAs, started to have the fruits from last couple of years.

But we also, our businesses, you know, like most of the pharmaceutical companies, with internal development plus the BDE, external innovation, we normally call, and we also marketed a few licensed-in assets to the market.

And again, mostly on the oncology side.

That's how we end up today.